Idenix Pharmaceuticals, Inc. (IDIX) Posts Q2 EPS Loss of $0.15, Revenues Miss Expectations
Tweet Send to a FriendGet Alerts IDIX Hot Sheet
Price: $4.06 --0%
EPS Growth %: +5.6%
Financial Fact:
Net loss: -30.75M
Today's EPS Names:
ZLC, TOL, TGT, More
EPS Growth %: +5.6%
Financial Fact:
Net loss: -30.75M
Today's EPS Names:
ZLC, TOL, TGT, More
Trade IDIX Now!
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) reported Q2 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.45 million.
The Company expects that its current cash, cash equivalents and the anticipated royalty payments associated with product sales of Tyzeka/Sebivo will be sufficient to satisfy its cash needs until at least the second quarter of 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The Company expects that its current cash, cash equivalents and the anticipated royalty payments associated with product sales of Tyzeka/Sebivo will be sufficient to satisfy its cash needs until at least the second quarter of 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Alvarion Ltd (ALVR) Narrows Q1 Loss
- Zoom Technologies, Inc. (ZOOM) Reports Q1 Loss of $0.01
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
